Oruka Therapeutics, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
Oruka Therapeutics, Inc. (ORKA) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $2.89 per share as of 2014-12-31, per its 10-K filed 2015-03-19.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2015-03-19
- 2014-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $2.89.
- 2013-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $3.76.
- 2012-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $18.28.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2014-12-31 | $2.89 10-K · filed 2015-03-19 |
| 2013-12-31 | $3.76 10-K · filed 2014-03-20 |
| 2012-12-31 | $18.28 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |